Ranbaxy gets 180-day exclusivity for Alzheimer’s generic

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Ranbaxy gets 180-day exclusivity for Alzheimer’s generic

Genéricos/Novedades | Posted 31/01/2011 0 Post your comment

On 30 November 2010, generics’ giant and India’s largest pharmaceutical manufacturer, Ranbaxy Laboratories, announced the launch of a generic version of Pfizer’s blockbuster Alzheimer’s treatment, Aricept (donepezil hydrochloride), in the US.

Ranbaxy, which is part of the Japanese Daiichi Sankyo Group, announced that it had received final approval from the FDA to manufacture and market donepezil hydrochloride tablets 5 and 10 mg, giving the company 180-day market exclusivity for being first to market in the US.

Aricept is indicated for the treatment of dementia of the Alzheimer’s type, and in patients with mild to moderate and severe Alzheimer’s disease. According to the Alzheimer’s Association, 5.3 million Americans have Alzheimer’s disease.

Aricept is the best-selling medicine in the Alzheimer’s disease market. Annual sales for Aricept 5 and 10 mg tablets were US$2.6 billion in 2010, so the 180-day market exclusivity is a major result for Ranbaxy.

Vice President of Trade Sales at Ranbaxy, Mr Bill Winter, said “we are pleased to announce the launch of donepezil, which … will benefit the US healthcare system by providing a more affordable treatment option to patients [and] which will have a positive impact on escalating US healthcare costs”.

Source: Ranbaxy